- 361 Downloads
Vismodegib is the first Hedgehog pathway inhibitor to be approved in the USA, where it is indicated for the treatment of adults with metastatic basal cell carcinoma (BCC), or with locally advanced BCC that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation. In an ongoing, noncomparative, phase II trial, oral vismodegib was effective in and had an acceptable tolerability profile in the treatment of patients with locally advanced or metastatic BCC.
- 1.National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®): basal cell and squamous cell skin cancers (version 2.2012). Fort Washington (PA): National Comprehensive Cancer Network, Inc.; 2012.Google Scholar
- 5.Erivedge™ (vismodegib) capsule for oral use: US prescribing information. South San Francisco (CA): Genentech, Inc.; 2012 Jan.Google Scholar
- 9.Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of the Hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update [abstract no. 8579]. 48th Annual Meeting of the American Society of Clinical Oncology; 2012 Jun 1–5; Chicago.Google Scholar